



HEDIS® results for 2019 BCN Advantage – Medicare

| HEDIS® Measure | BCN Advantage 2018 reporting (measurement year 2017) | BCN Advantage 2019 reporting (measurement year 2018) | CMS Stars 4 | CMS Stars 5 | NCOA 90th Percentile 2019 |
|---|--|--|-------------|-------------|---------------------------|
| *Adult BMI assessment | 98.54% | 99.76% | 96% | 99% | n/a |
| Antidepressant medication management — effective acute phase treatment | 78.18% | 79.02% | n/a | n/a | 79.41 |
| Antidepressant medication management — effective continuation phase treatment | 60.80% | 61.16% | n/a | n/a | 67% |
| *Breast cancer screening | 79.32% | 80.86% | 76% | 83% | n/a |
| *Colorectal cancer screening | 82.48% | 87.20% | 73% | 80% | n/a |
| Comprehensive diabetic care — HbA1c testing | 96.35% | 97.78% | n/a | n/a | 97.27% |
| *Comprehensive diabetic care — blood sugar controlled | 89.05% | 91.11% | 72% | 85% | n/a |
| Comprehensive diabetic care — HbA1c control <8.0% | 77.13% | 77.50 % | n/a | n/a | 78% |
| *Comprehensive diabetic care — medical attention for nephropathy | 97.57% | 98.89% | 95% | 97% | n/a |
| *Comprehensive diabetic care — eye examinations | 80.05% | 82.78% | 73% | 78% | n/a |
| Comprehensive diabetic care — blood pressure control | 68.37% | 75.28% | n/a | n/a | 81% |
| *Disease-modifying anti-rheumatic drug therapy for rheumatoid arthritis | 80.46% | 81.36% | 79% | 84% | n/a |
| Initiation and engagement of alcohol and other drug dependence treatment — initiation | 43.87% | 46.26% | n/a | n/a | 49.31% |
| Hospitalizations for potentially preventable complications (lower is better) | 0.93 | 0.76 | n/a | n/a | n/a |
| *Medication reconciliation post-discharge | 68.86% | 80.28% | 71% | 84% | n/a |
| Non-recommended PSA-based screening in older men (lower is better) | 40.38% | 38.99% | n/a | n/a | 16% |
| *Osteoporosis management in women who had a fracture | 50.81% | 69.61% | 50% | 67% | n/a |
| Persistence of beta-blocker treatment after heart attack | 91.44% | 91.89% | n/a | n/a | 95.45% |
| Pharmacotherapy management of COPD exacerbation — systemic corticosteroid | 79.15% | 83.39% | n/a | n/a | 78% |
| Pharmacotherapy management of COPD exacerbation — bronchodilators | 78.48% | 79.90% | n/a | n/a | 90% |
| *Statin therapy for patients with cardiovascular disease — therapy | 80.59% | 80.91% | 83% | 87% | n/a |
| Statin therapy for patients with cardiovascular disease — adherence | 76.65% | 77.28% | n/a | n/a | 88% |
| Statin therapy for patients with diabetes — adherence | 73.92% | 76.53% | n/a | n/a | 86% |
| Statin therapy for patients with diabetes — therapy | 72.08% | 74.03% | n/a | n/a | 80% |
| *Plan all-cause readmissions (lower is better) | 7.80% | 6% | 7% | 3% | n/a |

*CMS Stars for Medicare

Note: Not all measures are listed.

n/a indicates there is no benchmark available.